Dynamics of small molecule-enzyme interactions: Novel benzenesulfonamides as multi-target agents endowed with inhibitory effects against some metabolic enzymes


Gulec O., TÜRKEŞ C., ARSLAN M., Isik M., Demir Y., Duran H. E., ...Daha Fazla

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, cilt.759, 2024 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 759
  • Basım Tarihi: 2024
  • Doi Numarası: 10.1016/j.abb.2024.110099
  • Dergi Adı: ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aquatic Science & Fisheries Abstracts (ASFA), BIOSIS, CAB Abstracts, Chemical Abstracts Core, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Anadolu Üniversitesi Adresli: Evet

Özet

In contemporary medicinal chemistry, employing a singular small molecule to concurrently multi-target disparate molecular entities is emerging as a potent strategy in the ongoing battle against metabolic disease. In this study, we present the meticulous design, synthesis, and comprehensive biological evaluation of a novel series of 1,2,3-triazolylmethylthio-1,3,4-oxadiazolylbenzenesulfonamide derivatives (8a 8a-m ) as potential multi-target inhibitors against human carbonic anhydrase (EC.4.2.1.1, h CA I/II), alpha-glycosidase (EC.3.2.1.20, alpha-GLY), and alpha-amylase (EC.3.2.1.1, alpha-AMY). Each synthesized sulfonamide underwent rigorous assessment for inhibitory effects against four distinct enzymes, revealing varying degrees of h CA I/II, a-GLY, and a-AMY inhibition across the tested compounds. h CA I was notably susceptible to inhibition by all compounds, demonstrating remarkably low inhibition constants (KI) K I ) ranging from 42.20 f 3.90 nM to 217.90 f 11.81 nM compared to the reference standard AAZ (KI K I of 439.17 f 9.30 nM). The evaluation against h CA II showed that most of the synthesized compounds exhibited potent inhibition effects with K I values spanning the nanomolar range 16.44 f 1.53-70.82 f 4.51 nM, while three specific compounds, namely 8a-b and 8d , showcased lower inhibitory potency than other derivatives that did not exceed that of the reference drug AAZ (with a K I of 98.28 f 1.69 nM). Moreover, across the spectrum of synthesized compounds, potent inhibition profiles were observed against diabetes mellitus- associated alpha-GLY (KI K I values spanning from 0.54 f 0.06 mu M to 5.48 f 0.50 mu M), while significant inhibition effects were noted against alpha-AMY, with IC 50 values ranging between 0.16 f 0.04 mu M and 7.81 f 0.51 mu M) compared to reference standard ACR (KI K I of 23.53 f 2.72 mu M and IC 50 of 48.17 f 2.34 mu M, respectively). Subsequently, these inhibitors were evaluated for their DPPH center dot and ABTS+center dot + center dot radical scavenging activity. Moreover, molecular docking investigations were meticulously conducted within the active sites of h CA I/II, alpha-GLY, and alpha-AMY to provide comprehensive elucidation and rationale for the observed inhibitory outcomes.